Loading company…
Replay develops gene and cell technologies for treatments targeting cancer, rare diseases, and other conditions.
Founded in 2021, Replay develops immune silencing technologies and gene and cell treatments for conditions including solid tumors and diseases affecting the skin, eye, brain, and muscle. Its technologies include uCell™, synHSV™, DropSynth™, and Learned Ancestral Sequence Recognition (LASR). The company is based in California, US, raised USD 55 million in seed financing in July 2022, and received USD 1.5 million in grant funding from Bill & Melinda Gates Foundation Trust in November 2022.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in